Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignancies

Department of Gynecology, Catholic University, Rome, Italy.
British Journal of Cancer (Impact Factor: 4.84). 08/1990; 62(1):147-51. DOI: 10.1038/bjc.1990.248
Source: PubMed


Serum levels of TAG 72 were measured in 726 serum samples from patients with benign and malignant gynaecological conditions in order to evaluate the clinical usefulness of TAG 72 alone or in combination with other tumour markers. Sixty-six per cent of patients with ovarian cancer showed abnormal concentrations of TAG 72 antigen. A good correlation was also found between serial TAG 72 values and the clinical course of disease during chemotherapy and follow-up. In cervical and endometrial cancer abnormal TAG 72 values occurred in 23% and 14% of cases, while none of the patients with breast cancer had abnormal TAG 72 levels. Among patients with benign disease only one out of 12 patients (8%) with benign ovarian tumours and one of 15 patients with uterine fibromyomatosis (7%) showed high TAG 72 serum levels. However, the determination of TAG 72 did not increase the sensitivity of CA 125 and squamous cell carcinoma antigen (SCC), in ovarian and cervical cancer, respectively. The systemic administration of recombinant interferon alpha-2b to 15 patients with ovarian cancer and different basal levels of TAG 72 did not increase serum levels of the antigen.

10 Reads

  • Journal of Clinical Endocrinology &amp Metabolism 04/1993; 76(4):1075-1079. DOI:10.1210/jc.76.4.1075 · 6.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Serum levels of IL-6 were evaluated in a large group of patients with benign or malignant gynecological tumors. The results obtained were correlated with the patients' clinicopathological features and follow-up data. Using a highly sensitive immunoenzymatic method for the evaluation of serum IL-6 levels, we observed that > 5% of normal healthy women exhibited values within the range of 1.9-6 pg/ml. Using a cut-off of pg/ml, elevated levels of serum IL-6 were found in 53% of 45 patients with primary epithelial ovarian cancer and less frequently in patients with endometrial and cervical cancer (37% and 10% respectively). Elevated levels of IL-6 were occasionally seen in patients with benign disease. IL-6 serum levels appeared to be less sensitive than CA 125 in ovarian cancer diagnosis. In cancer patients, increased IL-6 serum levels were related to the presence of the tumor since all post-operative patients exhibited a marked decrease. In patients with advanced ovarian cancer post-operative levels of IL-6 correlated with residual disease. Very high levels of IL-6 were observed in the ascitic fluid of9 ovarian cancer patients, but IL-6 mRNA was not detected in tumor cells. This suggests that the increased production of IL-6 observed in ovarian cancer is reactive. Higher levels of IL-6 were found in patients unresponsive to chemotherapy, as compared with responsive ones. Univariate analysis of survival data suggests that increased IL-6 serum levels correlate with negative prognosis. © 1994 Wiley-Liss, Inc.
    International Journal of Cancer 05/1994; 57(3):318-323. DOI:10.1002/ijc.2910570305 · 5.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The serum glycan moieties of glycoproteins and the activities of glycosidases were analyzed in order to elucidate the metabolism of glycoprotein in uterine cervical cancer. Serum was collected from patients at different stages of cervical cancer before and after treatment. The results were analyzed using Student's t-test. The glycan moieties such as sialic acid and fucose were significantly elevated even in the early stages of carcinoma, whereas a significant elevation in hexose and hexosamine levels was observed only in the advanced stages. Among the investigated lysosomal glycohydrolases, beta-D-galactosidase, N-acetyl-beta-D-glucosaminidase and alpha-L-fucosidase activities were elevated significantly at all stages except for stage I. The altered levels of glycoproteins and glycosidases were reduced to near-normal levels after radiotherapy. The levels of glycan moieties and the activities of glycosidases can be used as diagnostic markers to assess the stage of cancer and can be used as prognostic markers during therapy.
    International Journal of Gynecology & Obstetrics 02/1995; 48(1):49-54. DOI:10.1016/0020-7292(94)02247-X · 1.54 Impact Factor
Show more

Similar Publications


10 Reads
Available from